Caligor supporting Puma's expanded access program for breast cancer therapy

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Voyagerix)
(Image: iStock/Voyagerix)

Related tags: Breast cancer, Cancer, Oncology

Caligor Opco LLC is providing regulatory and logistical management for Puma Biotechnology’s expanded access program (EAP) for its investigational breast cancer therapy, neratinib.

This program will provide access to neratinib for the treatment of early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors while neratinib is still an investigational agent​,” Karen Frascello, vice president of business development at Caligor Opco.

Caligor Opco manages regulatory, logistics, and supply chain needs for global access programs. It also sources, stores, and distributes comparator drugs for clinical trials.

Frascello explained the company helps advance the program by “efficiently meeting the needs of all stakeholders​,” which enables Puma to focus on neratinib clinical development and ongoing regulatory activities.

Caligor will also help Puma manage health care professional (HCP) requests for neratinib.

We will also communicate with HCPs to help manage neratinib treatment and facilitate access to re-supply of neratinib for patients​,” added Frascello.

Our clinical operations team will respond to general inquiries from US HCPs; explain the EAP requirements to HCPs; and assist in answering regulatory questions as well as those related to Institutional Review Board (IRB) approvals​,” she explained.

Additionally, the company will work the Puma’s drug supply personnel to coordinate neratinib shipments to physician practices or hospitals.

Currently, the US EAP is open and accepting unsolicited patient access requests to neratinib from HCPs.  

Frascello explained the program will close “if and when​” neratinib gains FDA approval. “The specific parameters of the program are set forth by Puma Biotechnology,​” she added.

Related news

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers